Latest & greatest articles for stroke

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on stroke or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on stroke and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for stroke

1922. Risk of cardiac events in atypical transient ischaemic attack or minor stroke. The Dutch TIA Study Group.

Risk of cardiac events in atypical transient ischaemic attack or minor stroke. The Dutch TIA Study Group. 1355211 1992 10 01 1992 10 01 2015 06 16 0140-6736 340 8820 1992 Sep 12 Lancet (London, England) Lancet Risk of cardiac events in atypical transient ischaemic attack or minor stroke. The Dutch TIA Study Group. 630-3 Proposed guidelines for the diagnosis of transient ischaemic attack (TIA) involve interpretation of symptoms, so it can be very difficult to distinguish a TIA from other (...) disorders, such as migraine, epilepsy, syncope, or neurosis. Atypical cerebral and visual events may be classified as TIA. To see whether TIA or stroke patients with atypical cerebral or visual symptoms are at high or low risk of cardiac complications, we prospectively followed 572 patients (entered into the Dutch multicentre TIA trial) with a diagnosis of TIA or minor ischaemic stroke, but whose symptoms did not fully accord with internationally accepted criteria. We compared their outcome

Lancet1992

1923. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators.

Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. 1406859 1992 11 23 1992 11 23 2013 11 21 0028-4793 327 20 1992 Nov 12 The New England journal of medicine N. Engl. J. Med. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. 1406-12 Nonrheumatic (...) atrial fibrillation is common among the elderly and is associated with an increased risk of stroke. We investigated whether anticoagulation with warfarin would reduce this risk. We conducted a randomized, double-blind, placebo-controlled study to evaluate low-intensity anticoagulation with warfarin (prothrombin-time ratio, 1.2 to 1.5) in 571 men with chronic nonrheumatic atrial fibrillation; 525 patients had not previously had a cerebral infarction, whereas 46 patients had previously had such an event

NEJM1992

1924. Physiotherapy intervention late after stroke and mobility.

Physiotherapy intervention late after stroke and mobility. 1559090 1992 05 13 1992 05 13 2010 09 07 0959-8138 304 6827 1992 Mar 07 BMJ (Clinical research ed.) BMJ Physiotherapy intervention late after stroke and mobility. 609-13 To determine whether the intervention of a physiotherapist improved mobility in patients seen more than one year after stroke. Randomised crossover trial comparing two groups offered intervention by a physiotherapist, one immediately after entry into the trial (...) and the other after a delay of three months. The intervention consisted of identifying problems and offering advice and help to solve the problems. Patients' homes in Oxfordshire. Patients who had reduced mobility due to a stroke more than one year before entry; 60 were recruited from a community stroke register and 34 in other ways. Standard measures of mobility including gait speed, functional ambulation categories, the Nottingham extended activities of daily living index, and individual items from

BMJ1992 Full Text: Link to full Text with Trip Pro

1925. The Bradford community stroke trial: results at six months.

The Bradford community stroke trial: results at six months. 1586821 1992 06 23 1992 06 23 2015 11 19 0959-8138 304 6834 1992 Apr 25 BMJ (Clinical research ed.) BMJ The Bradford community stroke trial: results at six months. 1085-9 Comparison of day hospital attendance and home physiotherapy for stroke patients leaving hospital to determine which service produces greater functional and social improvement for the patient, reduces emotional stress for the care giver, and lessens the need (...) for community support. Stratified, randomised trial of stroke patients attending day hospital two days a week or receiving home treatment from a community physiotherapist. The six month assessment results are reported in this paper. Patients over 60 years old resident within the Bradford metropolitan district discharged home after a new stroke with residual disability. Four day hospitals in two health authorities and domiciliary work undertaken by experienced community physiotherapists. Barthel index

BMJ1992 Full Text: Link to full Text with Trip Pro

1926. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke.

Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke. 1346819 1992 03 20 1992 03 20 2015 11 19 0140-6736 339 8791 1992 Feb 22 Lancet (London, England) Lancet Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke. 451-3 Antiphospholipid antibodies have been suggested as markers for a high risk of recurrent cardiovascular events in young (...) or IgM) was an independent risk factor for mortality, reinfarction, or non-haemorrhagic stroke. Although an increased proportion of survivors of a myocardial infarction have antiphospholipid antibodies, the presence of such antibodies is not a risk factor for subsequent coronary or cerebrovascular thrombosis. Sletnes K E KE Haematological Research Laboratory, Ullevål University Hospital, Oslo, Norway. Smith P P Abdelnoor M M Arnesen H H Wisløff F F eng Clinical Trial Journal Article Randomized

Lancet1992

1927. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group.

The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group. 1598096 1992 07 08 1992 07 08 2013 11 21 0028-4793 327 1 1992 Jul 02 The New England journal of medicine N. Engl. J. Med. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo (...) Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group. 1-6 Many trials in patients with acute myocardial infarction have demonstrated that thrombolytic therapy is not associated with an excessive risk of stroke, as compared with conventional treatment. However, the incidence of various forms of stroke in patients treated with different thrombolytic and antithrombotic regimens and the associated effect of risk factors for stroke are largely unknown. Strokes

NEJM1992

1928. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. 2046107 1991 07 15 1991 07 15 2016 10 17 0098-7484 265 24 1991 Jun 26 JAMA JAMA Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative (...) Research Group. 3255-64 To assess the ability of antihypertensive drug treatment to reduce the risk of nonfatal and fatal (total) stroke in isolated systolic hypertension. Multicenter, randomized, double-blind, placebo-controlled. Community-based ambulatory population in tertiary care centers. 4736 persons (1.06%) from 447,921 screenees aged 60 years and above were randomized (2365 to active treatment, 2371 to placebo). Systolic blood pressure ranged from 160 to 219 mm Hg and diastolic blood

JAMA1991

1929. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group.

A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group. 1922220 1991 11 05 1991 11 05 2013 11 21 0028-4793 325 18 1991 Oct 31 The New England journal of medicine N. Engl. J. Med. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group. 1261-6 Aspirin is known to improve (...) the outcome of patients who have had a cerebral transient ischemic attack, but the optimal dose of aspirin remains uncertain. Experimental evidence indicates that 30 mg of aspirin daily alters platelet aggregation more favorably than the 300-mg dose currently used in patients after transient ischemic attack or minor ischemic stroke. We assessed the effects of two doses of a water-soluble preparation of acetylsalicylic acid, or aspirin (30 mg vs. 283 mg a day), on the occurrence of death from all vascular

NEJM1991

1930. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.

Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. 1969567 1990 05 10 1990 05 10 2015 06 16 0140-6736 335 8693 1990 Apr 07 Lancet (London, England) Lancet Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. 827-38 There are 14 unconfounded randomised trials (...) of antihypertensive drugs (chiefly diuretics or beta-blockers): total 37,000 individuals, mean treatment duration 5 years, mean diastolic blood pressure (DBP) difference 5-6 mm Hg. In prospective observational studies, a long-term difference of 5-6 mm Hg in usual DBP is associated with about 35-40% less stroke and 20-25% less coronary heart disease (CHD). For those dying in the trials, the DBP difference had persisted only 2-3 years, yet an overview showed that vascular mortality was significantly reduced (2p

Lancet1990

1931. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study.

Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. 2407959 1990 04 12 1990 04 12 2013 11 21 0028-4793 322 12 1990 Mar 22 The New England journal of medicine N. Engl. J. Med. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. 863-8 Atrial fibrillation, even in the absence of rheumatic valvular disease, predisposes patients to embolic complications, but the role of antithrombotic therapy in the prevention of such complications has not been fully (...) clarified. We therefore performed a randomized, placebo-controlled trial to evaluate warfarin and aspirin individually as prophylaxis against ischemic stroke and systemic embolism (the primary events) in such patients. Patients eligible to receive warfarin (group 1) were assigned to warfarin (open label), aspirin (325 mg per day), or placebo (aspirin and placebo were given in a doubleblind fashion). Those who were not eligible for warfarin (group 2) received either aspirin or placebo in a double-blind

NEJM1990

1932. Randomised, double-blind, placebo-controlled trial of nimodipine in acute stroke. Trust Study Group.

Randomised, double-blind, placebo-controlled trial of nimodipine in acute stroke. Trust Study Group. 1978069 1990 12 21 1990 12 21 2016 11 23 0140-6736 336 8725 1990 Nov 17 Lancet (London, England) Lancet Randomised, double-blind, placebo-controlled trial of nimodipine in acute stroke. Trust Study Group. 1205-9 The value of oral nimodipine 120 mg per day for acute stroke was assessed in a randomised, double-blind, placebo-controlled multicentre study of 1215 patients. The primary end-point (...) was independence after 6 months, defined as a score of 60 or more on an activities of daily living (ADL) scale, the Barthel index. Patients were entered into the trial if they were aged over 40, became hemiparetic in the previous 48 h, were conscious, were able to swallow, and had been living independently before the stroke. At 6 months, 55% of the nimodipine group and 58% of the placebo group were independent, the odds ratio for independence on nimodipine being 0.88 (95% confidence limits 0.70-1.10

Lancet1990

1933. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators.

The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. 2233931 1990 12 11 1990 12 11 2013 11 21 0028-4793 323 22 1990 Nov 29 The New England journal of medicine N. Engl. J. Med. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. 1505-11 (...) Nonrheumatic atrial fibrillation increases the risk of stroke, presumably from atrial thromboemboli. There is uncertainty about the efficacy and risks of long-term warfarin therapy to prevent stroke. We conducted an unblinded, randomized, controlled trial of long-term, low-dose warfarin therapy (target prothrombin-time ratio, 1.2 to 1.5) in patients with nonrheumatic atrial fibrillation. The control group was not given warfarin but could choose to take aspirin. A total of 420 patients entered the trial

NEJM1990

1934. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group.

A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. 2761587 1989 09 21 1989 09 21 2013 11 21 0028-4793 321 8 1989 Aug 24 The New England journal of medicine N. Engl. J. Med. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. 501-7 We report the results of the Ticlopidine Aspirin (...) Stroke Study, a blinded trial at 56 North American centers that compared the effects of ticlopidine hydrochloride (500 mg daily) with those of aspirin (1300 mg daily) on the risk of stroke or death. The medications were randomly assigned to 3069 patients with recent transient or mild persistent focal cerebral or retinal ischemia. Follow-up lasted for two to six years. The three-year event rate for nonfatal stroke or death from any cause was 17 percent for ticlopidine and 19 percent for aspirin--a 12

NEJM1989

1935. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke.

The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. 2566778 1989 07 03 1989 07 03 2015 06 16 0140-6736 1 8649 1989 Jun 03 Lancet (London, England) Lancet The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. 1215-20 The Canadian American Ticlopidine Study (CATS) is a randomised, double-blind, placebo-controlled trial to assess the effect of ticlopidine (250 mg twice daily) in reducing the rate of subsequent occurrence of stroke, myocardial (...) infarction, or vascular death in patients who have had a recent thromboembolic stroke. Twenty-five centres entered 1072 patients into the study between 1 week and 4 months after their qualifying stroke. The patients were treated and followed for up to 3 years (mean 24 months). In the efficacy analysis, the event rate per year for stroke, myocardial infarction or vascular death, considered together, was 15.3% in the placebo group and 10.8% in the ticlopidine group, representing a relative risk reduction

Lancet1989

1936. Is the pharmacological treatment of mild to moderate hypertension cost effective in stroke prevention?

Is the pharmacological treatment of mild to moderate hypertension cost effective in stroke prevention? Is the pharmacological treatment of mild to moderate hypertension cost effective in stroke prevention? Is the pharmacological treatment of mild to moderate hypertension cost effective in stroke prevention? Malcolm L A, Kawachi I, Jackson R, Bonita R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) .) 1) Side effects of therapy are discussed but not included. 2) The costing methodology based on macro usage of health resources is of uncertain accuracy. 3) The paper makes a deliberately optimistic appraisal of therapy, in addition the type of model used is likely to be inaccurate, assuming a constant cost/benefit stream. Bibliographic details Malcolm L A, Kawachi I, Jackson R, Bonita R. Is the pharmacological treatment of mild to moderate hypertension cost effective in stroke prevention? New

NHS Economic Evaluation Database.1988

1937. A controlled trial of nimodipine in acute ischemic stroke.

A controlled trial of nimodipine in acute ischemic stroke. 3275894 1988 02 20 1988 02 20 2013 11 21 0028-4793 318 4 1988 Jan 28 The New England journal of medicine N. Engl. J. Med. A controlled trial of nimodipine in acute ischemic stroke. 203-7 Recent investigations suggest that increased cellular calcium concentrations may be implicated in neuronal death after ischemia. To determine whether treatment with a calcium-channel blocker would improve survival and neurologic outcome in acute (...) ischemic stroke, we enrolled 186 patients in a prospective, double-blind, randomized, placebo-controlled trial of nimodipine (30 mg every six hours), begun within 24 hours of the onset of symptoms of an acute ischemic stroke. During the four-week treatment period, mortality from all causes was significantly reduced with nimodipine as compared with placebo (8 deaths [8.6 percent] vs. 19 [20.4 percent]). The improvement in survival was restricted to men. During the follow-up period of six months

NEJM1988

1938. Haemodilution in acute stroke: results of the Italian haemodilution trial. Italian Acute Stroke Study Group.

Haemodilution in acute stroke: results of the Italian haemodilution trial. Italian Acute Stroke Study Group. 2448561 1988 03 16 1988 03 16 2016 11 23 0140-6736 1 8581 1988 Feb 13 Lancet (London, England) Lancet Haemodilution in acute stroke: results of the Italian haemodilution trial. Italian Acute Stroke Study Group. 318-21 In a multicentre clinical trial 1267 patients with hemispheric stroke of duration 12 h or less and haematocrit of 35% or more were prospectively randomised to either (...) haemodilution (by venesection and replacement of the same volume of dextran 40 in saline solution) or control treatment groups. In the haemodiluted group mean haematocrit declined from 43% to 37% at 48 h and this fall was maintained for seven days. A plain computed tomographic scan was obtained in all but 37 patients. 87% of the strokes were infarcts and 13% were haemorrhages. After six months the numbers of dead or severely disabled patients were equally distributed in the two treatment groups

Lancet1988

1939. The European Stroke Prevention Study (ESPS). Principal end-points. The ESPS Group.

The European Stroke Prevention Study (ESPS). Principal end-points. The ESPS Group. 2890951 1988 01 21 1988 01 21 2015 06 16 0140-6736 2 8572 1987 Dec 12 Lancet (London, England) Lancet The European Stroke Prevention Study (ESPS). Principal end-points. The ESPS Group. 1351-4 In a multicentre double-blind trial, 2500 patients with a clinical diagnosis of a recent cerebrovascular event of atherothrombotic origin (transient ischaemic attack, reversible ischaemic neurological deficit, or stroke (...) ) were randomised to receive either dipyridamole 75 mg plus acetylsalicylic acid 325 mg (DP-ASA, 1250 patients) or placebo (1250 patients) thrice daily. Follow-up was twenty-four months. On intention-to-treat analysis, 473 patients reached an end-point (stroke or death from any cause), 190 on DP-ASA and 283 on placebo. Survival curves for end-points showed 33% benefit in favour of the DP-ASA group (p less than 0.001). 108 patients died in the DP-ASA group and 156 in the placebo group (p less than

Lancet1987

1940. Double-blind randomised trial of intravenous glycerol in acute stroke.

Double-blind randomised trial of intravenous glycerol in acute stroke. 2880214 1987 03 24 1987 03 24 2015 06 16 0140-6736 1 8530 1987 Feb 21 Lancet (London, England) Lancet Double-blind randomised trial of intravenous glycerol in acute stroke. 405-8 The effects of intravenous glycerol in elderly patients with recent onset of acute ischaemic stroke were evaluated in a double-blind randomised controlled trial. 173 patients received either 500 ml of a 10% solution of glycerol in physiological

Lancet1987